Topics:

Rheumatology Network

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Recent Content

(AAOS2015) Total knee replacements appear successful for the relatively young and active as well as for those over 90. For people with the most preoperative pain, however, they may not help at all.

The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.

A recent interest in the effects of neutrophil extracellular traps in gout tophi could shed light on inflammatory processes in other autoimmune diseases.

(AAOS2015) The first study to assess the effect of steroid injections on the hip joint suggests that they may hasten joint degeneration, but the co-injected local anesthetic is also suspect.

The UK government's health assessment agency has found that combinations of traditional drugs offer results for rheumatoid arthritis not inferior to those of tumor necrosis factor inhibitors, although the latter work more quickly.

vaccine

Tofacitinib affects response to the pneumonia (but not the influenza) vaccine in rheumatoid arthritis patients, especially those also taking methotrexate,

Pfizer and Lilly will resume development of the anti-nerve growth factor monoclonal antibody tanezumab for osteoarthritis pain, after the FDA lifted its ban imposed due to adverse effects in animal trials.

By clicking Accept, you agree to become a member of the UBM Medica Community.